title: [Clinical efficacy of travoprost-timolol fixed combination on ocular hypotensive agents and ocular surface agents in Japanese glaucoma patients].
abstract: OBJECTIVE
  To investigate the clinical effects of travoprost-timolol fixed combination on ocular hypotensive agents, ocular surface agents and adherence in Japanese glaucoma patients.
  
  
  METHODS
  28 Japanese glaucoma patients, who had used topical prostaglandin F2alpha analogue (28 eyes; PG group), were assigned to treatment with travoprost-timolol fixed combination. Reduction of intraocular pressure (IOP), grades of conjuctival follicle, conjuctival injection and keratoepitheliopathy, as well as interviews for topical administration, were evaluated. 38 patients, who switched from the topical prostaglandin F2alpha analogue and a beta-blocker to travoprost-timolol fixed combination (38eyes: PG+BB group) were also evaluated in the same manner.
  
  
  RESULTS
  While IOP was significantly reduced in the PG group, IOP was not changed in the PG+BB group. Both groups showed no significant changes in scores for conjuctival follicle, keratoepitheliopathy, or interview.
  
  
  CONCLUSIONS
  These results suggest that travoprost-timolol fixed combination reduces IOP and produces low toxicity on the ocular surface.
authors.affiliation: Department of Ophthalmology, Hiroshima Kinen Hospital. tkana@hiroshima-u.ac.jp
authors.forename: Takashi
authors.initials: T
authors.lastname: Kanamoto
authors.affiliation: Department of Ophthalmology, Hiroshima University Hospital.
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Kiuchi
authors.affiliation: lchioka Eye Clinic.
authors.forename: Ikuko
authors.initials: I
authors.lastname: Ichioka
authors.affiliation: Onishi Eye Clinic.
authors.forename: Toru
authors.initials: T
authors.lastname: Onishi
authors.affiliation: Osada Eye Clinic.
authors.forename: Kenji
authors.initials: K
authors.lastname: Osada
authors.affiliation: Kimura Eye and Internal Medicine Hospital.
authors.forename: Wataru
authors.initials: W
authors.lastname: Kimura
authors.affiliation: Department of Ophthalmology, Asa-Shimin Hospital.
authors.forename: Tatsunori
authors.initials: T
authors.lastname: Suchiro
authors.affiliation: Nagaya Eye Clinic.
authors.forename: Manabu
authors.initials: M
authors.lastname: Nagaya
authors.affiliation: Hirota Eye Clinic.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Hirota
authors.affiliation: Department of Ophthalmology, Shobara-Red Cross Hospital.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Mukai
authors.affiliation: Miyoshi Eye Clinic.
authors.forename: Teruyuki
authors.initials: T
authors.lastname: Miyoshi
authors.affiliation: Miyoshi Eye Clinic.
authors.forename: Hironori
authors.initials: H
authors.lastname: Yoshi
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000494:pharmacology; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000494:pharmacology; D044466:Asian People; D003008:Cloprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D003315:Cornea / Q000187:drug effects; D015237:Dinoprost / Q000008:administration & dosage / Q000031:analogs & derivatives; D004338:Drug Combinations; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D017060:Patient Satisfaction; D011795:Surveys and Questionnaires; D013999:Timolol / Q000008:administration & dosage* / Q000494:pharmacology; D000069557:Travoprost; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D004338:Drug Combinations; D009883:Ophthalmic Solutions; D003008:Cloprostenol; D013999:Timolol; D015237:Dinoprost; D000069557:Travoprost